Literature DB >> 28743531

Metabolic regulation of glioma stem-like cells in the tumor micro-environment.

Tom M Thomas1, John S Yu2.   

Abstract

Cancer metabolism has emerged as one of the most interesting old ideas being revisited from a new perspective. In the early 20th century Otto Warburg declared metabolism the prime cause in a disease of many secondary causes, and this statement seems more prescient in view of modern expositions into the true nature of tumor evolution. As the complexity of tumor heterogeneity becomes more clear from a genetic perspective, it is important to consider the inevitably heterogeneous metabolic components of the tumor and the tumor microenvironment. High grade gliomas remain one of the most difficult to treat solid tumors, due in part to the highly vascularized nature of the tumor and the maintenance of more resistant stem-like subpopulations within the tumor. Maintenance of glioma stem cells (GSCs) requires specific alterations within the cells and the greater tumor microenvironment with regards to signaling and metabolism. Specific niches within gliomas help foster the survival of stem-like sub-populations of cells with high tumorigenicity and high metabolic plasticity. Understanding these maintenance pathways and the metabolic dependencies within the niche may highlight potential avenues of addressing tumor resistance and recurrence in glioma patients.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer metabolism; Cancer stem cells; Glioblastoma; Glioma stem cells; Microenvironment

Mesh:

Year:  2017        PMID: 28743531      PMCID: PMC5790120          DOI: 10.1016/j.canlet.2017.07.014

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  82 in total

1.  CD133+ niches and single cells in glioblastoma have different phenotypes.

Authors:  Karina Christensen; Henrik Daa Schrøder; Bjarne Winther Kristensen
Journal:  J Neurooncol       Date:  2010-12-24       Impact factor: 4.130

Review 2.  Glioblastoma, cancer stem cells and hypoxia.

Authors:  Eli E Bar
Journal:  Brain Pathol       Date:  2010-11-30       Impact factor: 6.508

Review 3.  Brain tumor stem cells: Molecular characteristics and their impact on therapy.

Authors:  David L Schonberg; Daniel Lubelski; Tyler E Miller; Jeremy N Rich
Journal:  Mol Aspects Med       Date:  2013-07-04

Review 4.  Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways.

Authors:  Nadine Rohwer; Thorsten Cramer
Journal:  Drug Resist Updat       Date:  2011-04-03       Impact factor: 18.500

5.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

6.  MYC/PGC-1α Balance Determines the Metabolic Phenotype and Plasticity of Pancreatic Cancer Stem Cells.

Authors:  Patricia Sancho; Emma Burgos-Ramos; Alejandra Tavera; Tony Bou Kheir; Petra Jagust; Matthieu Schoenhals; David Barneda; Katherine Sellers; Ramon Campos-Olivas; Osvaldo Graña; Catarina R Viera; Mariia Yuneva; Bruno Sainz; Christopher Heeschen
Journal:  Cell Metab       Date:  2015-09-10       Impact factor: 27.287

7.  Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells.

Authors:  Zhizhong Li; Shideng Bao; Qiulian Wu; Hui Wang; Christine Eyler; Sith Sathornsumetee; Qing Shi; Yiting Cao; Justin Lathia; Roger E McLendon; Anita B Hjelmeland; Jeremy N Rich
Journal:  Cancer Cell       Date:  2009-06-02       Impact factor: 31.743

8.  SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity.

Authors:  Rosaria Maria Rita Gangemi; Fabrizio Griffero; Daniela Marubbi; Marzia Perera; Maria Cristina Capra; Paolo Malatesta; Gian Luigi Ravetti; Gian Luigi Zona; Antonio Daga; Giorgio Corte
Journal:  Stem Cells       Date:  2009-01       Impact factor: 6.277

9.  TrkA overexpression enhances growth and metastasis of breast cancer cells.

Authors:  C Lagadec; S Meignan; E Adriaenssens; B Foveau; E Vanhecke; R Romon; R-A Toillon; B Oxombre; H Hondermarck; X Le Bourhis
Journal:  Oncogene       Date:  2009-03-30       Impact factor: 9.867

10.  A restricted cell population propagates glioblastoma growth after chemotherapy.

Authors:  Jian Chen; Yanjiao Li; Tzong-Shiue Yu; Renée M McKay; Dennis K Burns; Steven G Kernie; Luis F Parada
Journal:  Nature       Date:  2012-08-23       Impact factor: 49.962

View more
  15 in total

1.  LncRNA MACC1-AS1/MACC1 enhances the progression of glioma via regulating metabolic plasticity.

Authors:  Dahai Zheng; Daliang Che; Famu Lin; Xiang Wang; Lenian Lu; Jianmin Chen; Xiaobing Xu
Journal:  Cell Cycle       Date:  2020-08-20       Impact factor: 4.534

Review 2.  O-GlcNAc in cancer: An Oncometabolism-fueled vicious cycle.

Authors:  John A Hanover; Weiping Chen; Michelle R Bond
Journal:  J Bioenerg Biomembr       Date:  2018-03-29       Impact factor: 2.945

Review 3.  Metabolic heterogeneity and adaptability in brain tumors.

Authors:  Christian E Badr; Daniel J Silver; Florian A Siebzehnrubl; Loic P Deleyrolle
Journal:  Cell Mol Life Sci       Date:  2020-06-06       Impact factor: 9.261

4.  Tunneling nanotubes: A bridge for heterogeneity in glioblastoma and a new therapeutic target?

Authors:  Varun Subramaniam Venkatesh; Emil Lou
Journal:  Cancer Rep (Hoboken)       Date:  2019-05-08

5.  Up-regulation of miR-663a inhibits the cancer stem cell-like properties of glioma via repressing the KDM2A-mediated TGF-β/SMAD signaling pathway.

Authors:  Lei Wang; Bojuan Lang; Youdong Zhou; Jinyang Ma; Keqi Hu
Journal:  Cell Cycle       Date:  2021-08-23       Impact factor: 5.173

6.  Downregulation of the CCL2/CCR2 and CXCL10/CXCR3 axes contributes to antitumor effects in a mouse model of malignant glioma.

Authors:  Kenji Shono; Izumi Yamaguchi; Yoshifumi Mizobuchi; Hiroshi Kagusa; Akiko Sumi; Toshitaka Fujihara; Kohei Nakajima; Keiko T Kitazato; Kazuhito Matsuzaki; Hideyuki Saya; Yasushi Takagi
Journal:  Sci Rep       Date:  2020-09-17       Impact factor: 4.379

Review 7.  Functional Roles of Long Non-Coding RNAs (LncRNAs) in Glioma Stem Cells.

Authors:  Lei Wang; Zhengwen He
Journal:  Med Sci Monit       Date:  2019-10-08

8.  Bromodomain inhibitor jq1 induces cell cycle arrest and apoptosis of glioma stem cells through the VEGF/PI3K/AKT signaling pathway.

Authors:  Naiyan Wen; Baofeng Guo; Hongwu Zheng; Libo Xu; Hang Liang; Qian Wang; Ding Wang; Xuyang Chen; Shengnan Zhang; Yang Li; Ling Zhang
Journal:  Int J Oncol       Date:  2019-08-29       Impact factor: 5.650

9.  SHP2 inhibition enhances the anticancer effect of Osimertinib in EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated stemness.

Authors:  Leiming Xia; Fan Yang; Xiao Wu; Suzhi Li; Chen Kan; Hong Zheng; Siying Wang
Journal:  Cancer Cell Int       Date:  2021-07-03       Impact factor: 5.722

Review 10.  The complement system in glioblastoma multiforme.

Authors:  T A M Bouwens van der Vlis; J M Kros; D A M Mustafa; R T A van Wijck; L Ackermans; P M van Hagen; P J van der Spek
Journal:  Acta Neuropathol Commun       Date:  2018-09-12       Impact factor: 7.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.